Science Corporation’s subretinal implant and specialised glasses combination, PRIMA, has been shown to provide durable, long-term gains in vision to patients with a degenerative eye condition called ...

New ACOG guidance says benefits outweigh risks for most women, with nonhormonal options for those who can’t take hormones ...

“ACOG recommends selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) ...

Heidi Borst is a writer, editor and certified nutrition coach who loves health and wellness. Before joining Forbes Health as a Staff Writer, her work appeared in The New York Times, The Washington ...

Investors have survived September, the historically worst month of the year for stock market returns. Outside of February (which has an average return that's just barely negative), September is the ...

Hayden Panettiere died from the toxic effects of fentanyl, 4-ANPP, alprazolam, methocarbamol and quetiapine, according to the Greenville County Coroner's Office. The manner of death was ruled an ...

Current use of oral menopausal hormone therapy (commonly known as hormone replacement therapy or HRT) is associated with an increased risk of blood clots in the legs or lungs regardless of dose or ...

When it comes to balancing hormonal changes during the transition to menopause, less can be more. Researchers at the University of São Paulo (USP) in Brazil demonstrated this when testing an ...

Katharine Paljug is a financial writer and editor with over a decade of industry experience. Her writing has covered nearly every aspect of the financial world, from investing in forex to paying for ...

The Council decided today to prolong the restrictive measures targeting those responsible for undermining or threatening the territorial integrity, sovereignty and independence of Ukraine for another ...

Every few years, a new TV show comes along that’s more popular than anyone expects. Last year, the show that took the world by storm was The Pitt, which wasn’t exactly easy to see coming, especially ...

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader ...